Unmasking bias and MDMA-assisted therapy
Abstract
<p>On August 9th the US Food and Drug Administration’s (FDA) rejected 3,4-methylenedioxymethamphetamine assisted therapy (MDMA-AT) as a treatment for post-traumatic stress disorder (PTSD) despite seemingly positive trial results. A major reason cited was functional unmasking, which combined with enthusiasm about MDMA, raised concerns about the objectivity of these trials. Here, we define what is 'unmasking bias' and calculate its magnitude for two drugs, ketamine and escitalopram, where data was available from the literature. Our results show that unmasking bias for these two drugs is larger than the treatment vs. control effect size for MDMA. Our findings do not prove that effects of MDMA-AT are entirely or even partially due to unmasking, however, they indicate that MDMA-AT’s effect sizes are not too large to be due to unmasking.</p>
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.